 | | Vol. 11.35 – 5 September, 2023 |
| |
|
|
| Researchers performed combined bulk and single-cell whole-genome sequencing and copy number variation analysis of 30 patients treated with anti-B cell maturation antigen (BCMA) and/or anti-GPRC5D CAR T/bispecific T cell engager therapy.
[Nature Medicine] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists combined genome-wide CRISPR screens in target cancer cells to identify pathways that regulate γδ T cell killing and butyrophilin 3A cell surface expression.
[Nature] |
|
|
|
| Investigators reported a cell-barcoding method for the multiplexed longitudinal profiling of cells in vivo using single-cell RNA sequencing.
[Nature Biomedical Engineering] |
|
|
|
| The authors presented an integrated single-cell RNA-Seq study of 19 immune checkpoint blockade (ICB)-naive and nine ICB-treated brain metastases samples from their own and published data sets.
[Journal Of Clinical Investigation] |
|
|
|
| Researchers established intratumoral CD103+CD8+ tumor-infiltrating cells density as a determinant of neoadjuvant chemoimmunotherapy efficacy in cancers.
[Cancer Communications] |
|
|
|
| Using single-cell transcriptomics and genome-wide epigenetic profiling, investigators established that “variable immunoreceptor–expressing myeloids” were myeloid cells unrelated to lymphocytes.
[Science Advances] |
|
|
|
| Researchers used a network-based approach for integrating a set of 186 inborn errors of immunity with predominant autoimmunity/autoinflammation into a comprehensive map of human immune dysregulation, which they termed “AutoCore”.
[Science Advances] |
|
|
|
| Scientists revealed that low METTL3 expression correlated with poor response to immune checkpoint blockade, and overexpressing METTL3 in tumor cells could enhance the efficacy of anti-PD-1 therapy in papillary thyroid cancer and anaplastic thyroid cancer.
[Cell Death & Differentiation] |
|
|
|
| Third-generation protease-activated receptor 1 CAR-T cells exhibited antitumor activity in the tumor microenvironment, providing innovative CAR-T cell immunotherapy against pancreatic ductal adenocarcinoma.
[3D Printing And Additive Manufacturing] |
|
|
|
|
| Scientists summarize the identification and characterization of neoantigens and the clinical application of neoantigen-based T cell receptor (TCR)-T immunotherapy strategies.
[Molecular Cancer] |
|
|
|
|
| Cancer vaccines utilizing mRNA vaccine technology have such potential that ARPA-H, a newly established White House-originated program, has made it the focus of its first-ever grant.
[Yale School of Medicine] |
|
|
|
|
| October 2 – 4, 2023
Boston, Massachusetts, United States |
|
|
|
|
| | National Cancer Institute – Bethesda, Maryland, United States |
|
|
|
| | Cedars-Sinai – Los Angeles, California, United States |
|
|
|
| | University of Regensberg – Heidelberg, Germany |
|
|
|
| | The Scripps Research Institute – La Jolla, California, United States |
|
|
|
| | University of California, Berkeley – Berkeley, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
